Carisma Therapeutics Plans to Delist from Nasdaq and End SEC Reporting Obligations Carisma Therapeutics has announced its plan to voluntarily delist from Nasdaq and deregister its common stock to terminate SEC reporting obligations. Understanding their strategy is vital.

Carisma Therapeutics Plans to Delist from Nasdaq and End SEC Reporting Obligations #USA #Philadelphia #Carisma_Therapeutics #OTC_Markets #CARM

Halper Sadeh LLC Launches Investigations on NVEE, CARM, HLGN for Shareholder Rights Halper Sadeh LLC is conducting investigations into NV5 Global, Carisma Therapeutics, and Heliogen for potential violations of securities laws and shareholder rights.

Halper Sadeh LLC Launches Investigations on NVEE, CARM, HLGN for Shareholder Rights #USA #New_York #Halper_Sadeh_LLC #Carisma_Therapeutics #NV5_Global

Carisma Therapeutics Announces Strategic Review Amid Corporate Restructuring Efforts to Secure Future Growth Carisma Therapeutics Inc. has initiated a strategic review to explore alternatives for enhancing its liver fibrosis and oncology programs while minimizing operational costs.

Carisma Therapeutics Announces Strategic Review Amid Corporate Restructuring Efforts to Secure Future Growth #United_States #Philadelphia #oncology #Carisma_Therapeutics #liver_fibrosis

Carisma Therapeutics Set to Present at H.C. Wainwright Cell Therapy Conference Carisma Therapeutics will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference, showcasing its innovative macrophage-focused therapies.

Carisma Therapeutics Set to Present at H.C. Wainwright Cell Therapy Conference #USA #Philadelphia #Carisma_Therapeutics #Cell_Therapy #Michael_Klichinsky

Carisma Therapeutics to Showcase Innovations at Oppenheimer Healthcare Conference Carisma Therapeutics is set to present its pioneering macrophage-focused therapies at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11.

Carisma Therapeutics to Showcase Innovations at Oppenheimer Healthcare Conference #United_States #Philadelphia #Healthcare_Conference #Carisma_Therapeutics #Steven_Kelly

Carisma Therapeutics Implements Strategic Changes to Streamline Pipeline and Focus on Key Therapies Carisma Therapeutics announces strategic restructuring to prioritize in vivo therapies for fibrosis, oncology, and autoimmune diseases while reducing workforce.

Carisma Therapeutics Implements Strategic Changes to Streamline Pipeline and Focus on Key Therapies #United_States #Philadelphia #biotechnology #Carisma_Therapeutics #macrophage_therapy

Carisma Therapeutics CEO to Feature in Fireside Chat at HealthCONx Conference Carisma Therapeutics Inc. will have its CEO participate in the upcoming Evercore ISI HealthCONx Conference, highlighting their pioneering immunotherapy platform.

Carisma Therapeutics CEO to Feature in Fireside Chat at HealthCONx Conference #USA #Philadelphia #HealthCONx #Carisma_Therapeutics #Steven_Kelly